Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-SARS-CoV-2 VHH antibody
- Development stage
- Preclinical
- Lead developer
- COGNANO
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Inhalation, Intranasal
01
Overview
COGNANO's anti-SARS-CoV-2 VHH antibody is a preclinical-stage neutralizing nanobody (single-domain antibody) derived from alpaca immune repertoires. It specifically targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. By binding to the spike protein, the antibody sterically hinders the interaction between the virus and the host cell's ACE2 receptor, thereby neutralizing the viral infection. The VHH modality offers advantages such as high stability, small size, and the potential for alternative delivery routes like inhalation or nasal spray, as well as broad-spectrum activity against various SARS-CoV-2 variants. This candidate is being developed for both therapeutic and diagnostic applications.
- Other names
- COGNANO SARS-CoV-2 VHHanti-SARS-CoV-2 nanobodyanti-SARS-CoV2 nanobodyanti-SARS-CoV 2 nanobody
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on anti-SARS-CoV-2 VHH antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-SARS-CoV-2 VHH antibody.